{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:03Z","timestamp":1792788063366,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.schres.2010.07.012","type":"journal-article","created":{"date-parts":[[2010,8,8]],"date-time":"2010-08-08T04:55:38Z","timestamp":1281243338000},"page":"225-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":565,"title":["Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"123","author":[{"given":"Christine","family":"Rummel-Kluge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Komossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Asenjo","family":"Lobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Kissling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2010.07.012_bb0005","series-title":"Cochrane Schizophrenia Group in The Cochrane Library Chichester","author":"Adams","year":"2006"},{"key":"10.1016\/j.schres.2010.07.012_bb0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/07315724.2003.10719316","article-title":"Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies","volume":"22","author":"Anderson","year":"2003","journal-title":"J. Am. Coll. Nutr."},{"key":"10.1016\/j.schres.2010.07.012_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.05.009","article-title":"A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study","volume":"104","author":"Arango","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.07.012_bb0020","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.schres.2008.10.023","article-title":"Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients","volume":"108","author":"Bai","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.07.012_bb0025","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1152\/japplphysiol.00160.2005","article-title":"Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease","volume":"99","author":"Bassuk","year":"2005","journal-title":"J. Appl. Physiol."},{"issue":"Suppl 18","key":"10.1016\/j.schres.2010.07.012_bb0030","first-page":"27","article-title":"Dyslipidemia and atypical antipsychotic drugs","volume":"65","author":"Casey","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2010.07.012_bb0035","series-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.schres.2010.07.012_bb0040","first-page":"A42","article-title":"Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states","volume":"3","author":"Colton","year":"2006","journal-title":"Prev. Chronic Dis."},{"key":"10.1016\/j.schres.2010.07.012_bb0045","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.schres.2008.07.006","article-title":"Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study","volume":"105","author":"Daumit","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.07.012_bb0050","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.eurpsy.2009.01.005","article-title":"Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)","volume":"24","author":"De Hert","year":"2009","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2010.07.012_bb0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Der-Simonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.schres.2010.07.012_bb0060","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4088\/JCP.v65n0219","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"65","author":"Diabetes Expert Group","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2010.07.012_bb0065","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4088\/JCP.v69n0401","article-title":"Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges","volume":"69","author":"Fleischhacker","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2010.07.012_bb0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1527-3458.2007.00008.x","article-title":"Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials","volume":"13","author":"Greenberg","year":"2007","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.schres.2010.07.012_bb0075","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1034\/j.1600-0447.2003.00130.x","article-title":"Shared decision making in psychiatry","volume":"107","author":"Hamann","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2010.07.012_bb0080","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.157.6.975","article-title":"Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study","volume":"157","author":"Henderson","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.07.012_bb0085","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1161\/01.CIR.97.11.1095","article-title":"Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors","volume":"97","author":"Hennekens","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.schres.2010.07.012_bb0090","series-title":"Innere Medizin Herold","author":"Herold","year":"2009"},{"key":"10.1016\/j.schres.2010.07.012_bb0095","series-title":"Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 Chichester","author":"Higgins","year":"2005"},{"key":"10.1016\/j.schres.2010.07.012_bb0100","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/01.jcp.0000161501.65890.22","article-title":"Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders","volume":"25","author":"Kinon","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2010.07.012_bb0105","series-title":"Risperidone versus other atypical antipsychotics for schizophrenia (protocol)","author":"Komossa","year":"2007"},{"key":"10.1016\/j.schres.2010.07.012_bb0110","first-page":"CD006627","article-title":"Ziprasidone versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2010.07.012_bb0115","first-page":"CD006752","article-title":"Sertindole versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2010.07.012_bb0120","first-page":"CD006569","article-title":"Aripiprazole versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2010.07.012_bb0125","first-page":"CD006654","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia","volume":"3","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2010.07.012_bb0130","first-page":"CD006628","article-title":"Zotepine versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2010.07.012_bb0135","first-page":"CD006624","article-title":"Amisulpride versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2010.07.012_bb0140","first-page":"CD006625","article-title":"Quetiapine versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2010.07.012_bb0145","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.07.012_bb0150","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1017\/S0033291709005455","article-title":"Second generation antipsychotics for schizophrenia: can we resolve the conflict?","volume":"39","author":"Leucht","year":"2009","journal-title":"Psychol Med."},{"key":"10.1016\/j.schres.2010.07.012_bb0155","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.schres.2010.07.012_bb0160","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4088\/JCP.v63n0509","article-title":"A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1year","volume":"63","author":"Meyer","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2010.07.012_bb0165","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","article-title":"Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1","volume":"101","author":"Meyer","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.07.012_bb0170","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.schres.2008.04.023","article-title":"Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1","volume":"103","author":"Meyer","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.07.012_bb0175","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2010.07.012_bb0180","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1056\/NEJM199506293322607","article-title":"The primary prevention of coronary heart disease in women","volume":"332","author":"Rich-Edwards","year":"1995","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.schres.2010.07.012_bb0185","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jpsychires.2009.03.002","article-title":"The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year","volume":"43","author":"Schorr","year":"2009","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2010.07.012_bb0190","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.psychres.2010.03.011","article-title":"Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia","volume":"177","author":"Vancampfort","year":"2010","journal-title":"Psychiatry Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996410014271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996410014271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:23:07Z","timestamp":1760296987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996410014271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":38,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0920996410014271"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2010.07.012","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2010.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}